MORE DOCUMENTATION OF OVER-VACCINATION RISKS
The following document to the British government authorities to address the serious cat and dog health issues of over-vaccination was prepared by Cane Health Concern, www.canine-health-concern.org.uk
Canine Health Concern
PO Box 7533, Rait, Perthshire PH2 1AD
Telephone 01821 670410
10 February 2010
TO STEVE DEAN,
VETERINARY MEDICINES DIRECTORATE
KT15 3LSDear Professor Dean
We are writing with regard to the unnecessary vaccination of dogs and cats, and calling for decisive and immediate action from the Veterinary Medicines Directorate.
Despite repeated requests over many years, the VMD – a government department – has failed to take action to ensure that veterinary vaccines are administered no more frequently than is necessary, or to warn and protect the public from spurious claims on the part of veterinary vaccine manufacturers and veterinary surgeons. Independent duration of immunity studies have been available since the 1970s to show that immunity to viral disease in dogs and cats persists for years or the life of the animal, and that annual vaccination is not required.
To protect the pet owning public, the VMD must insist upon clarity within datasheets for MLV vaccines, and make it known that MLV vaccines do not need to be routinely ‘boosted’ every year, or even every three years. We are asking the VMD to withdraw license authorisations, and accompanying datasheets, which do not reflect the known science. We are asking for a public statement from the VMD to protect British citizens and their pets.
Such guidance would enable local authorities and kennels to stop demanding proof of annual vaccinations – which the science shows are unnecessary, and potentially damaging to the animals. Educated pet owners do not wish to be forced to pay for a veterinary procedure which is unnecessary and potentially harmful to their family pets, and nor should they.
We are also asking the VMD to provide clarification and guidance on the subject of non-core vaccines (such as the leptospirosis vaccine) which come with potentially serious adverse effects, and which should only be given in the face of a real disease threat.
The World Small Animal Veterinary Association (WSAVA) guidelines define non-core vaccines as “those that are required by only those animals whose geographical location, local environment or lifestyle places them at risk of contracting specific infections”. As such, non-core vaccines should not be routinely administered on an annual basis.
We are aware, however, that no independent data exists to show the prevalence of core or non-core canine and feline diseases in the UK, which means that the public is at the mercy of the vaccine manufacturers’ marketing machines and their scare tactics.
You are fully aware that vaccine manufacturers’ revaccination recommendations in the UK conflict with the latest international dog and cat vaccination guidelines, as do the recommendations to clients from vets in practice in the UK.
I refer specifically to Intervet’s yearly ‘National Vaccination Month’ which seeks to frighten pet owners into revaccinating pets whose ‘boosters have lapsed by 18 months or more’. Our members have written to their MPs to challenge this marketing campaign in the past, and have received a document from yourself in response. You state in your document:
“Directive 2001/82/EC, as amended, is the European framework for the regulation of veterinary medicinal products, including vaccines, and has been transposed into the UK legislation. The legislation determines the quality, safety and efficacy requirements for a marketing authorisation to be granted. In addition, the product must meet the minimum mandatory requirements of the European Pharmacopoeia. Assessment of data provided by the pharmaceutical companies is carried out in the UK by the VMD’s veterinarians and scientists.”
You add: “… all claims made by the manufacturers must be supported with data from specific trials for each category of each species recommended for vaccination, by each recommended route of administration and using the proposed schedule of vaccination.”
This is precisely the problem: The VMD has historically asked for one year’s proof of efficacy from vaccine manufacturers – even before EU Directive 2001/82/EC – thereby allowing vaccine manufacturers to market products under the guise that they must be re-administered every year. The same applies to the three-year vaccines. Were you to insist upon longer DOI data, the over-vaccination of companion animals would cease, providing licenses for one- and three-year vaccines were withdrawn. It is known, for example, that only a limited number of veterinary practices in the UK have abandoned yearly boosters in favour of the available three-yearly boosters.
In fact, were you to take the independent DOI studies on board, as adopted by the World Small Animal Veterinary Association, the American Animal Hospital Association, the American Veterinary Medical Association, the Australian Veterinary Association, and now the Australian Pesticides and Veterinary Medicines Authority (your Australian counterpart), such data and their accompanying trials from manufacturers would not be required so long as an appropriate immune response could be demonstrated. You must by now be familiar with the advice of the world’s experts in this field, that “once immunity to viral disease exists, it persists for years or life”? Such a statement was based upon the fact that a number of different vaccine brands were used in their DOI studies.
The Position Statement from the Australian Pesticides and Veterinary Medicines Authority states clearly that, “The international veterinary community is now increasingly supporting the position that annual re-vaccination with core vaccines is not required on a life-long basis,” and that, as a result, “does not support the retention of label statements that direct or imply a universal need for life-long annual revaccinations with core vaccines” … “is of the view that product labels should be amended to align with that policy,” and “is working with vaccine registrants with a view to updating labels”.
I would like to know why the Veterinary Medicines Directorate has been ignoring the known science in this regard since Canine Health Concern first brought the science to government attention in the early 1990s, and why it has consistently failed to act on behalf of pet owners and their pets.
A survey of vets participating in Intervet’s National Vaccination Month by Canine Health Concern and its members last year showed that vets are needlessly giving the full puppy and kitten series to adult dogs and cats ‘for the price of a booster’. They are engaged in a sales promotion that promotes a practice that is not required (annual vaccination), and offers an incentive that is not required (a full puppy/kitten series for adult animals who have ‘lapsed’ by 18 months). As such, they are obtaining a pecuniary advantage by deceiving the pet owning public.
Intervet is apparently aware of the fact that dogs have not ‘lapsed’ within 18 months, according to their own research. Please note their statement that protection is provided for a minimum of three years:
Vet Ther. 2005 Spring;6(1):5-14.
Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
Intervet Inc, 29160 Intervet Lane, PO Box 318, Millsboro, DE 19966, USA.
A challenge-of-immunity study was conducted to demonstrate immunity in dogs 3 years after their second vaccination with a new multivalent, modified-live vaccine containing canine adenovirus type 2 (CAV-2), canine parvovirus (CPV), and canine distemper virus (CDV). Twenty-three seronegative pups were vaccinated at 7 and 11 weeks of age. Eighteen seronegative pups, randomized into groups of six dogs, served as challenge controls. Dogs were kept in strict isolation for 3 years following the vaccination and then challenged sequentially with virulent canine adenovirus type 1 (CAV-1), CPV, and CDV. For each viral challenge, a separate group of six control dogs was also challenged. Clinical signs of CAV-1, CPV, and CDV infections were prevented in 100% of vaccinated dogs, demonstrating that the multivalent, modified-live test vaccine provided protection against virulent CAV-1, CPV, and CDV challenge in dogs 7 weeks of age or older for a minimum of 3 years following second vaccination.
By failing to make a statement of the known science, by failing to require longer DOI data from manufacturers, and by failing to remove one-year vaccines from the market, the VMD is facilitating the unethical practice of annual vaccination.
The WSAVA guidelines recommend: “We should aim to vaccinate every animal, and to vaccinate each individual less frequently.” These international guidelines also recommend that, “we should aim to reduce the ‘vaccine load’ on individual animals in order to minimise the potential for adverse reactions to vaccine products”.
UK vets in practice seem reluctant to adhere to international recommendations, and their professional bodies have failed to provide direction to their members in this regard. It therefore lies with the government and its servants to protect the pet owning public and their pets.
The WSAVA guidelines specifically advise that dogs properly vaccinated with MLV core CDV, CPV-2 and CAV-2 vaccines (distemper, parvovirus and adenovirus) “would have ≥98% protection from disease”. They recommend that dogs should not be vaccinated more frequently than every three years, and that immunity to viral disease lasts for at least seven years, but probably for life. This is based on direct challenge studies, and on serology. They call for annual checkups and possibly titer tests to replace revaccination each year.
Specifically, the WSAVA states:
“Vaccines should not be given needlessly. Core vaccines should not be given any more frequently than every three years.” Please note that this does not mean that dogs and cats should be vaccinated every three years. It is a political concession to mollify vets who do not wish to lose all of their booster income.
The 2003 American Animal Hospital Association canine vaccine guidelines state that “there is no scientific basis for the recommendation to revaccinate dogs annually with many of the current vaccines that provide years of immunity.”
Dr Ronald D Schultz, a member of the World Small Animal Veterinary Association Guidelines Group notes:
“The one year [revaccination] recommendation was not determined by any scientifically validated studies nor will one find in the literature publications that demonstrate a need for annual vaccination with many of the products in use.”
The 2003 AAHA guidelines state:
“When MLV vaccines are used to immunize a dog, memory cells develop and likely persist for the life of the animal. Resident memory cells respond rapidly providing an anamnestic immune response at the time of challenge (infection) with the pathogen.”
The WSAVA guidelines also note: “Most vaccinated dogs will have a persistence of serum antibody (against core vaccine antigens) for many years. For core vaccines there is excellent correlation between the presence of antibody and protective immunity and there is long DOI (duration of immunity) for these products.”
The government, through the VMD, should be advocating titer testing in place of revaccination.
The RCVS, the BSAVA, and their members, are using VMD-approved datasheet guidelines to provide an excuse to revaccinate animals which do not need revaccinating. As UK veterinary bodies and their members cannot be persuaded to acknowledge and act upon the known science as adopted by their international peers, it lies with government and its servants to stop facilitating such acts.
No medical procedure should be performed if it is unnecessary, and all care should be taken to minimise the potential for adverse reactions.
The Veterinary Medicines Directorate has failed in its responsibility. The following paragraph is taken from the VMD website:
“The vision of the VMD is the responsible, safe and effective use of veterinary medicinal products. In working towards achieving this vision the VMD aims to protect public health, animal health, the environment and promote animal welfare by assuring the safety, quality and efficacy of veterinary medicines.”
The British public relies upon the VMD to make the science known when corporations and professional bodies do not. Transparency, and accountability, are the minimum requirements.
I put it to you that the VMD is overly concerned with supporting the financial interests of its ‘customers’. The VMD’s reports and accounts, and its website, clearly illustrate that customers are multi-national corporations, followed at the bottom of the list by the pet owning public and their pets.
In your own document, drafted after members of the public wrote to their MPs about this subject in 2009, you stated:
“Neither the European and national legislation, nor the VMD, requires that vaccines be administered annually.”
It therefore lies with the VMD to stop this practice. It is unnecessary and potentially harmful. Please do not reply to tell us that vaccine reactions are very rare, as this will simply reinforce your allegiance to multi-nationals. The WSAVA report itself recognises “that there is gross under-reporting of vaccine-associated adverse events”.
This letter is written on behalf of the hundreds of pet owners who have contacted Canine Health Concern after their dogs were made ill or died from unnecessary vaccine procedures, and whose illnesses and deaths remain unreported and unacknowledged. It is signed by veterinarians from around the world, and by some of the animal guardians who join us in calling for an end to a needless and potentially harmful veterinary practice.
Catherine O’Driscoll, Canine Health Concern, for Oliver, Prudence and Samson
Rob Ellis, Canine Health Concern, for Samson and Jazar
Richard Allport BVetMed, VetMFHom, MRCVS
Stephen Blake BS, DVM, CVA, CVH
Dr Kim Bloomer VND
Michael W Fox BVetMed, PhD, DSC, MRCVS
Jean Hofve DVM
Patricia Monahan Jordan DVM, CVA, CTCVH & Herbology
Nicholas Larkins BVSc DSc MRCVS
Clare Middle BVMS CVA CertIAVH
James Newns Bvet Med MRCVS
Roger Meacock MRCVS
Barbara Noeldner DVM
Richard Pitcairn DVM PhD
Darla Rewers, DVM
Cheryl Sears MVB VetMFHom MRCVS
Charissa Smith BVSc DipAc, DipStrucBal, CertHom,
Erin Zamzow DVM
Liz Jay BA(Hons), for Lulu
Lisa Lister, for Puzzle
Terry and Satu Bateman, for Baron, Eiger and Brogan
Jens and Christina Diron, for Tallinn
Eve Kueh for Trekkie
Maggie Marshall, for Fleur and Brucie
Gill Aitken VN PhD, for Bill
Elizabeth Smith, for Hoocha and Bertie Bull
Julie Arnold, for Jess
Barbara Halliday for Nora
Alison Ingram BA(Hons), for Oskar
Heather Peterson, for Ben
Pat Nightingale, for Lady
Julia Roth Nicholson, for Poppy
Mandy Payne, for Gunner
Eileen Tuulos, for Tia Maria and KC
Christine Rogers, for Sasha
Victoria Herbert, for Luna and River
Linda Bland, for Cully, Freya and Rosie
Bet Hargreaves, for Ailsa
Christine Bailey BA, for Tasha
Wendy & Garry Galt for Bailey, Sandy, Sarah, Carson, and Sage
Jytte Smith, for Zoe
Barbara Burgess for Zilzie and Patch
Antonia Bancroft for Bandit, Fay and Hamish
Jan Vallance BA(Hons) MSc, for Gunn
Anne van Poelwijck, for Chatter, Rose and Mandy
Judith Coveney BA/Ed, for Elsie
Barbara Clark AAMET, for Rosie
Anne Aitken PASIACT , for Tansy
Jennie Wilcock-Bates, for Poacher
Veronica Steel, for Millie
Debbie Hill, for Max
Judith Longman, for Shah
Trisha Scott, for Hannah
Madeline Pook, for Barnaby
Sylvia Walker, for Tailor
Steve and Alison Pearce, for Minx
Sally Cronk, For Sadie
Joyce McDowell, for Bailee
Gail Gwesyn-Price APDT, BIPDT, ACA, NCAB, CSI, for Abel
Kath Rayson, for Oliver
Douglas M Decker SLC, for Alex, Casey and Nikko
Edward McKenzie-Clark, for Hamish
George and Christine Ridley, for Shem
Sarah Rutherford BA Hons, for Kerrie
Christine Wyndham-Thomas, for Lucky
Lisbeth Gjetnes RN, for Zoe and Pippa
Chris Salter, for Dexter and Leo
Pat White, for Sabre
Nick and Lisa Healing, for Jake
John and Sheryl Kobel and Family, Kingdom Cavaliers, for India
Morgana Washington, Welcome Home Sanctuary, for Samson
Janis Mattson, for Mocha Joe
Liz Levelle ND Dip Hom, for Pepper
Bruce and Jean Hellingsworth, for Morgan
Debbie Sutherland, for Mojo and Rocky
Barb McKee, for Bailey, Vegas and Muggins
Anne Grose, for Merrie and Stitch
Judy Williams RGN NDN MAR, for Teifi
Gary Robert Smith, BSc Hons MAPM
Deborah Molwuka BSc(Hons)
Sandy and David Bridger
Doreen Simpkins RGN, SCM, RHV, CSWM BA
Mari-Carmen and Edward Carson
Alexandra McGough BSc
Sarah Hold BHSAI
Robert P Warwick
Cheralyn Lewis BSc BA
Helen Roberts BSc Hons
Helen-Kimball-Brooke BA MA MBA FRSA LCPH MCHE RMANIM
David and Patricia Bryan
Rev Peter Cawood
Martin J Schor M.D. F.A.C.S., Diplomat, American Board Of Urology, Fellow, American College Of Surgeons
Deborah Gornall MBIPDT KCAI, Tinklebury Papillons and Chihuahuas, A.P.D.T.
Sandra Brigola, Von Hapsburg Danes
Patricia Sears, BIPDT (Advanced Instructor) APDT FDTCB
Joan M. Anderson, for Bene
1. Schultz, RD. and F.W. Scott. Canine & Feline Immunization. In: Symposium on Practical Immunology. R.D. Schultz, Ed., Vet Clinics of N. Am., Nov. 1978, W.B. Saunders Co.
2. Schultz, R.D. Current and Future Canine and feline vaccination programs. Vet Med 3: No. 3, 233-254, 1998.
3. R.D. Schultz / Veterinary Microbiology 117 (2006) 75–79
4. Abdelmagid, O.Y., Larson, L., Payne, L., Tubbs, A., Wasmoen, T., Schultz, R., 2004. Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus and distemper virus experimental challenges. Vet. Ther. Fall 5 (3), 173–186.
5. Carmichael, L.E., 1999. Canine viral vaccines at a turning point—a personal perspective. In: Schultz, R.D. (Ed.), Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. Academic Press, San Diego, pp. 289–307.
6. Elston, T., Rodan, I., Flemming, D., et al., 1988. Report of the American association of feline practitioners and academy of feline medicine advisory panel on feline vaccines. J. Am. Vet. Med. Assoc. 212, 227–241.
7. Gill, M., Srinivas, J., Morozov, I., Smith, J., Anderson, C., Glover, S., Champ, D., Chu, H., 2004. Three-year duration of immunity for canine distemper, adenovirus, and parvovirus after vaccination with a multivalent canine vaccine. Int. J. Appl. Res. Vet. Med. 2 (4), 227–234.
8. Green, C.E., Schultz, R.D., Ford, R.B., 2001. Canine vaccination. Vet. Clin. North Am. Sm. An. Pract. Vet. 31 (3), 473–492.
9. Janeway, C.A., Travers, L.J., Walmport, M. (Eds.), 2001. Immunobiology. fifth ed. Garland Publishing, New York, pp. 412–420.
10. Larson, L.J., Sawchuck, S., Schultz, R.D., 2002. Duration of vaccinal immunity in a population of clinic dogs. In: Proceedings 83rd Meeting, Conf. Res. Work Anim. Dis. St. Louis, Missouri (Abstract 75P).
11. Larson, L.J., Schultz, R.D., 1997. Comparison of selected canine vaccines for their ability to induce protective immunity against CPV-2 infection. Am. J. Vet. Res. 58 (4), 360–363.
12. Mouzin, D.E., Lorenzen, M.J., Haworth, J.D., King, V.L., 2004a. Duration of serologic responses to five viral antigens in dogs. JAVMA 224 (1), 55–60.
13. Mouzin, D.E., Lorenzen, M.J., Haworth, J.D., King, V.L., 2004b. Duration of serologic response to three viral antigens in cats. JAVMA 224 (1), 61–66.
14. Paul, M.A., Appel, M. J., et al., 2003. Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force: 2003 Canine Vaccine Guidelines. Recommendations and Supporting Literature.
15. Phillips, T.R., Schultz, R.D., 1992. Canine and feline vaccines. In: Kirk, R.W., Bonagura, J.D. (Eds.), Current Veterinary Therapy XI. W.B. Saunders Co., Philadelphia, pp. 202–206.
16. Richards, J., Rodan, I. 2000. 2000 Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Vaccines.
17. Rimmelzwaan, G.F., Osterhaus, A.D., 1997. The immune response. In: Pastoret, P.P. (Ed.), Veterinary Vaccinology. Elsevier Science, Amsterdam, pp. 55–67.
18. Scott, F.W., Geissinger, C.M., 1999. Long-term immunity in cats vaccinated with an inactivated trivalent vaccine. Am. J. Vet. Res. 60, 652–658.
19. Schultz, R.D., Appel, M.J., Carmichael, L.E., 1977. Canine vaccines and immunity. In: Kirk, R.W. (Ed.), Current Veterinary Therapy VI. WB Saunders Co., Philadelphia, pp. 1271–1275.
20. Schultz, R.D., Scott, F.W., 1978. Canine and feline immunization. Vet. Clin. North Am. 8 (4), 755–768.
21. Schultz, R.D., 1980. Theory and practice of immunization. In: Kirk, R.W. (Ed.), Current 285 Veterinary Therapy VII.W.B. Saunders Co., Philadelphia, pp. 1248–1251.
22. Schultz, R.D., Appel, M.J., Carmichael, L.E., 1980. Update on canine immunizations. In: Kirk, R.W. (Ed.), Canine Veterinary Therapy VII. WB Saunders Co., Philadelphia, pp. 1252–1255.
23. Schultz, R.D., 1998. Current and future canine and feline vaccination programs. Vet. Med. 93, 233–254.
24. Schultz, R.D., Conklin, S., 1998. The immune system and vaccines. Comp. Cont. Educ. Pract. Vet. 20, 5–18.
25. Schultz, R.D. (Ed.), 1999. Veterinary Vaccines and Diagnostics Chap. IV Canine and Feline Vaccines, Advances in Veterinary Medicine, vol. 41. Academic Press, San Diego, pp. 289–358.
26. Schultz, R.D., 1999b. Duration of immunity to canine vaccines: what we know and don’t know. In: Proceedings canine infectious diseases: from clinics to molecular pathogenesis, Cornell University, p. 22.
27. Schultz, R.D., 2000. Considerations in designing effective and safe vaccination programs for dogs. In: Carmichael, L.E. (Ed.), Recent Advances in Canine Infectious Diseases. International Veterinary Information Service, http://www.ivis.org/.
28. Schultz, R.D., 2004. Results presented at 2004 American College of Veterinary Internal Medicine Convention, Minneapolis MN and American Veterinary Medical Association Convention, Philadelphia PA and available in printed material ‘‘Canine Distemper and Vaccination’’ from Merial Limited, Duluth, GA.
29. R.D. Schultz / Veterinary Microbiology 117 (2006) 75–79 79
30. Veterinary Therapeutics, Vol. 5, No. 3, Fall 2004
31. AVMA Council on Biologic and Therapeutic Agents’ report on cat and dog vaccines. JAVMA 221(10): 1401–1407, 2002.
32. Paul MA, Appel M, Barrett R, et al: Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force: Executive summary and 2003 canine vaccine guidelines and recommendations. JAAHA 39:119–131, 2003 [published erratum appears in JAAHA 39(3):225, 2003].
33. Smith CA: Current concepts: Are we vaccinating too much? JAVMA 207(4):421–425, 1995.
34. Bohm M, Thompson H, Weir A, et al: Serum antibody titres to canine parvovirus, adenovirus and distemper virus in dogs in the UK which had not been vaccinated for at least three years. Vet Rec 154(15): 457–463, 2004.
35 Tizard I, Ni Y: Use of serologic testing to assess immune status of companion animals. JAVMA 213(1): 54–60, 1998.
36. Schultz RD, Conklin S: Serologic (antibody) analysis is an excellent indicator for “immunologic memory” following vaccination for any disease and specific indication of protective immunity for certain diseases. The immune system and vaccine challenges for the 21st century. Compend Contin Educ Pract Vet 20(suppl 8C):5–18, 1998.
37. Appel MJ, Summers BA: Canine distemper: Current status, in Carmichael L (ed): Recent Advances in Canine Infectious Diseases. Ithaca, NY, International Veterinary Information Service, Nov. 23, 1999. (Available at www.ivis.org/advances/Infect_Dis_Carmichael/appel/ chapter_frm.asp; accessed Aug. 18, 2004.)
38. Truyen U: Canine parvovirus, in Carmichael L (ed): Recent Advances in Canine Infectious Diseases. Ithaca, NY, International Veterinary Information Service, Jan. 26, 2000. (Available at www.ivis.org/advances/ Infect_Dis_Carmichael/truyen/chapter_frm.asp; accessed Aug. 18, 2004.)
39. Appel MJ: Forty years of canine vaccination. Adv Vet Med 41:309–324, 1999.
40. Dodds WJ. Immune-mediated diseases of the blood. Adv Vet Sci Comp Med 1983;27:163-196.
41. Dodds WJ. Estimating disease prevalence with health surveys and genetic screening. Adv Vet Sci Comp Med 1995;39:29-96.
42. Dodds WJ. More bumps on the vaccine road. Adv Vet Med 1999;41:715-732.
43. Hogenesch H, Azcona-Olivera J, Scott-Moncrieff C, Snyder PW, Glickman LT. Vaccine-induced autoimmunity in the dog. Adv Vet Med 1999;41:733-744.
44. Schultz R. Current and future canine and feline vaccination programs. Vet Med 1998;93:233-254.
35. Tizard I. Risks associated with use of live vaccines. J Am Vet Med Assoc 1990;196:1851-1858.
46. Twark L, Dodds WJ. Clinical use of serum parvovirus and distemper virus antibody titers for determining revaccination strategies in healthy dogs. J Am Vet Med Assoc 2000;217:1021-1024.
47. Tizard I, Ni Y. Use of serologic testing to assess immune status of companion animals. J Am Vet Med Assoc 1998;213:54-60.
48. Phillips TR, Jensen JL, Rubino MJ, Yang WC, Schultz RD. Effects of vaccines on the canine immune system. Can J Vet Res 1989;53:154-160.
49. Duval D, Giger U. Vaccine-associated immune-mediated haemolytic anaemia in the dog. J Vet Intern Med 1996;10:290-295.
50. Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun 1996;9:699-703.
51. May C, Hammill J, Bennett, D. Chinese shar pei fever syndrome: a preliminary report. Vet Rec 1992;131:586-587.
52. Day MJ, Penhale WJ. Immune-mediated disease in the old English sheepdog. Res Vet Sci 1992;53:87-92.
53. Dougherty SA, Center SA. Juvenile onset polyarthritis in akitas. J Am Vet Med Assoc 1991;198:849-855.
54. Scott-Moncrieff JCR, Snyder PW, Glickman LT, Davis EL, Felsburg PJ. Systemic necrotizing vasculitis in nine young beagles. J Am Vet Med Assoc 1992;201:1553-1558.
55. Wilbur LA, Evermann JF, Levings RL, et al. Abortion and death in pregnant bitches associated with a canine vaccine contaminated with blue tongue virus. J Am Vet Med Assoc 1994;204:1762-1765.
56. Happ GM. Thyroiditis—a model canine autoimmune disease. Adv Vet Sci Comp Med 1995;39:97-139.
57. Rivas AL, Tintle L, Meyers-Wallen V, Scarlett JM, van Tassell CP. Inheritance of renal amyloidosis in Chinese shar-pei dogs. J Hered 1993;84:438-442.
58. Journal of the American Animal Hospital Association May/June 2001, Vol. 37
59. Bilateral subcutaneous fibrosarcomas in a cat following feline parvo-, herpes- and calicivirus vaccination. De Man MM, Ducatelle RV. Journal of Feline Medicine & Surgery 2007 Oct; 9(5): 432-434. www.ncbi.nlm.nih.gov
60. Clinical use of serum parvovirus and distemper virus antibody titers for determining revaccination strategies in healthy dogs. Lisa Twark, DVM; W. Jean Dodds, DVM. Journal of the American Veterinary Medical Association. October 1, 2000, Vol. 217, No. 7, Pages 1021-1024. avmajournals.avma.org
61. Do postvaccinal sarcomas occur in Australian cats? G Burton and KV Mason. Aust Vet J 1997; 75:102-106. www.ncbi.nlm.nih.gov
62. Effects of vaccines on the canine immune system. T R Phillips, J L Jensen, M J Rubino, W C Yang, and R D Schultz. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison 53706. Can J Vet Res. 1989 April; 53(2): 154–160. www.pubmedcentral.nih.gov
63. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. Kass PH, Barnes WG Jr, Spangler WL, Chomel BB, Culbertson MR. Department of Epidemiology and Preventive Medicine, School of Veterinary Medicine, University of California, Davis 95616-8735. J Am Vet Med Assoc. 1993 Aug 1;203(3):396-405. www.ncbi.nlm.nih.gov
64. Feline Vaccine-associated Fibrosarcoma: Morphologic Distinctions. S. S. Couto, S. M. Griffey, P. C. Duarte and B. R. Madewell. Vet Pathol 39:33-41 (2002). www.vetpathology.org
65.Fibrosarcoma with Typical Features of Postinjection Sarcoma at Site of Microchip Implant in a Dog: Histologic and Immunohistochemical Study. M. Vascellari, E. Melchiotti and F. Mutinelli. Istituto Zooprofilattico Sperimentale delle Venezie, Histopathology Department, Viale dell’Universita 10, 35020 Legnaro (PD), Italy. Vet Pathol 43:545-548 (2006). www.vetpathology.org
66. Fibrosarcomas at presumed sites of injection in dogs: characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas. Vascellari M, Melchiotti E, Bozza MA, Mutinelli F. Istituto Zooprofilattico Sperimentale delle Venezie, Histopathology Department, Viale dell’Universita 10, 35020 Legnaro (PD), Italy. J Vet Med A Physiol Pathol Clin Med. 2003 Aug;50(6):286-91. www.ncbi.nlm.nih.gov
67. Histology and Immunohistochemistry of Seven Ferret Vaccination-site Fibrosarcomas.
J. S. Munday, N. L. Stedman and L. J. Richey. Athens Diagnostic Laboratory and Department of Veterinary Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA. Vet Pathol 40:288-293 (2003). www.vetpathology.org
68. Practical significance of rabies antibodies in cats and dogs
Michel F. Aubert. Centre national d’études vétérinaires et alimentaires, Laboratoire d’études sur la rage et la pathologie des animaux sauvages, Malzéville, France. Revue Scientifique et Technique 1992 Sept; 11(3): 735-60. www.ncbi.nlm.nih.gov
69. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986–1996). Elizabeth Hershey, DVM; Karin U. Sorenmo, CMV, DACVIM; Mattie J. Hendrick, VMD, DACVP; Frances S. Shofer, PhD; David M. Vail, DVM, DACVIM. Journal of the American Veterinary Medical Association. January 1, 2000, Vol. 216, No. 1, Pages 58-61. avmajournals.avma.org
70. Pulmonary and mediastinal metastases of vaccination-site sarcoma in a cat.
D. G. Rudmann, W. G. Van Alstine, F. Doddy, G. E. Sandusky, T. Barkdull and E. B. Janovitz.
Genentech, Inc., South San Francisco, CA 94080, USA. Veterinary Pathology, Vol 33, Issue 4, Pages 466-469. www.vetpathology.org
71. The potential role of inflammation in the development of postvaccinal sarcomas in cats.
Macy DW, Hendrick MJ. School of Veterinary Medicine, Colorado State College, Fort Collins 80523, USA. Vet Clin North Am Small Anim Pract. 1996 Jan;26(1):103-9. www.ncbi.nlm.nih.gov
72. Vaccine-associated Rhabdomyosarcoma with Spinal Epidural Invasion and Pulmonary Metastasis in a Cat. H.-W Chang, S.-Y Ho, H.-F Lo, Y.-C Tu, C.-R Jeng, C.-H Liu, F.-I Wang and V. F. Pang. Vet Pathol 43:55-58 (2006). www.vetpathology.org
73. Vaccine Site-Associated Sarcoma and Malignant Lymphoma in Cats: A Report of Six Cases (1997–2002). Bruce R. Madewell, VMD, Diplomate ACVIM (Oncology Internal Medicine), Tracy L. Gieger, DVM, Diplomate ACVIM (Internal Medicine), Patricia A. Pesavento, DVM, PhD and Michael S. Kent, DVM, Diplomate ACVIM (Oncology). Journal of the American Animal Hospital Association 40:47-50 (2004). www.jaaha.org
74. Adjuvants in Veterinary Vaccines: Modes of Action and Adverse Effects.
Anna R. Spickler and James A. Roth. Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA. Journal of Veterinary Internal Medicine 2003 May; 17(3): 273–281. apt.allenpress.com
75. Adverse Vaccine Reactions. W. Jean Dodds, DVM. www.noble-leon.com
76. Are we vaccinating too much?Cairn A. Smith, DVM, Journal of the American Veterinary Medical Association (JAVMA) August 15, 1995; Vol. 207, No. 4, Pages 421-425.
77. Avoiding Vaccine Reactions in Dogs and Cats. Craig E. Greene. 28th World Congress of the World Small Animal Veterinary Association: October 24 – 27, 2003: Bangkok, Tailand. www.vin.com
78. Feline Postvaccinal Sarcoma: A 2004 Update. Histovet Surgical Pathology. www.histovet.com
79. Feline Vaccine-Associated Sarcomas. Barbara E. Kitchell, DVM, PhD, DACVIM. 30 th World Congress of the World Small Animal Veterinary Association: May 11 – 14, 2005: Mexico City, Mexico. www.vin.com/proceedings
80. Human Illness Associated with Use of Veterinary Vaccines. Ruth L Berkelman.
81. Infectious Disease Prevention Change is in the Wind. Richard B. Ford, DVM, MS, DACVIM, DACVPM (Hon). 30 th World Congress of the World Small Animal Veterinary Association: May 11 – 14, 2005: Mexico City, Mexico. www.vin.com/proceedings
82. Injection Site and Vaccine Associated Sarcomas: New Advances for a New Millennium.
Gregory K. Ogilvie, DVM, DACVIM (Internal Medicine, Oncology). 29th World Congress of the World Small Animal Veterinary Association: October 6 – 9, 2004: Rhodes, Greece. www.vin.com
83. Update on Feline Fibrosarcoma. Patrick Devauchelle, DVM 27 WSAVA CONGRESS.
84. Vaccination Protocols for Dogs Predisposed to Vaccine Reactions. W. Jean Dodds, DVM
Journal of the American Animal Hospital Association. May/June 2001, Vol. 37, Pages 211-214.
85. Vaccine-Associated Feline Sarcoma Task Force: Roundtable Discussion – The current understanding and management of vaccine-associated sarcomas in cats. JAVMA: June 1, 2005; Vol. 226, No. 11. www.avma.org
86. Vaccine-associated feline sarcomas. Wallace B. Morrison, DVM, MS, DACVIM; Robin M. Starr, DVM, MEd; and the Vaccine-Associated Feline Sarcoma Task Force. Report of the Vaccine-Associated Feline Sarcoma Task Force from the Journal of the AVMA, Vol 218, No. 5, March 1, 2001, pp. 697-702.
87. Vaccine-Associated Sarcomas in the Cat. Glenna Mauldin. World Small Animal Veterinary Association World Congress: 2001: Vancouver. www.vin.com
88. Vaccines of the Present and Future. Alice Wolf. Small Animal Veterinary Association World Congress: 2001: Vancouver. www.vin.com
89. 2006 AAHA Canine Vaccine Guidelines, Revised. Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force. www.aahanet.org
90. The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel Report.
Journal of the American Veterinary Medical Association (JAVMA). November 1, 2006; Vol. 229, No. 9, Pages 1405-1441. www.aafponline.org
91. WSAVA Guidelines 2007: http://www.wsava.org/PDF/Misc/VGG_09_2007.pdf
92. APVMA’s Position Statement on Dog and Cat Vaccination Protocols http://www.apvma.gov.au/news_media/news/2010/2010-01-21_vaccination_position.php